DDB2 and keloid: Based on the high expression characteristics of CDK7 and DDB2, targeted therapeutic strategies can be developed in the future: For example, combining CDK7 inhibitors (THZ1, alvocidib) with local drug delivery systems (nanogels) for precise local injection into keloid lesions to reduce systemic toxicity.